Advocacy Wealth Management Services LLC Continues to Hold Stake in Illumina, Inc. (ILMN)

Advocacy Wealth Management Services LLC maintained its position in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 600 shares of the life sciences company’s stock at the end of the second quarter. Advocacy Wealth Management Services LLC’s holdings in Illumina were worth $104,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisory Services Network LLC acquired a new stake in Illumina during the first quarter worth $117,000. Gemmer Asset Management LLC raised its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Patten Group Inc. raised its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. NN Investment Partners Holdings N.V. raised its stake in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the last quarter. Finally, Probity Advisors Inc. acquired a new stake in Illumina during the first quarter worth $204,000. Hedge funds and other institutional investors own 93.73% of the company’s stock.

Shares of Illumina, Inc. (ILMN) traded up 0.79% on Tuesday, hitting $173.09. The stock had a trading volume of 811,765 shares. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $189.48. The firm has a market cap of $25.27 billion, a PE ratio of 35.03 and a beta of 0.84. The firm’s 50-day moving average price is $177.31 and its 200 day moving average price is $165.72.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.71 EPS. On average, equities research analysts predict that Illumina, Inc. will post $3.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/07/18/advocacy-wealth-management-services-llc-continues-to-hold-stake-in-illumina-inc-ilmn.html.

ILMN has been the topic of a number of recent analyst reports. TheStreet upgraded Illumina from a “c+” rating to a “b” rating in a research note on Thursday, April 6th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 target price on the stock. in a research note on Tuesday, April 11th. Bank of America Corporation increased their target price on Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Leerink Swann reiterated a “buy” rating on shares of Illumina in a research note on Wednesday, April 5th. Finally, Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $191.00 target price on the stock in a research note on Tuesday, April 4th. Four analysts have rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $166.30.

In related news, EVP Omead Ostadan sold 1,672 shares of the company’s stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $172.73, for a total value of $288,804.56. Following the completion of the sale, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at approximately $4,532,780.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total value of $300,995.63. Following the completion of the sale, the senior vice president now directly owns 10,936 shares of the company’s stock, valued at $2,045,797.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,248 shares of company stock valued at $19,720,123. Insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply